PL1641483T3 - Białka fuzyjne - Google Patents
Białka fuzyjneInfo
- Publication number
- PL1641483T3 PL1641483T3 PL04753440T PL04753440T PL1641483T3 PL 1641483 T3 PL1641483 T3 PL 1641483T3 PL 04753440 T PL04753440 T PL 04753440T PL 04753440 T PL04753440 T PL 04753440T PL 1641483 T3 PL1641483 T3 PL 1641483T3
- Authority
- PL
- Poland
- Prior art keywords
- fusion proteins
- reduced
- immnunogenic
- disorders
- derivatives
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47788003P | 2003-06-12 | 2003-06-12 | |
| US57090804P | 2004-05-13 | 2004-05-13 | |
| PCT/US2004/016611 WO2004110472A2 (en) | 2003-06-12 | 2004-06-10 | Fusion proteins |
| EP04753440A EP1641483B1 (en) | 2003-06-12 | 2004-06-10 | Fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1641483T3 true PL1641483T3 (pl) | 2008-07-31 |
Family
ID=33555478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04753440T PL1641483T3 (pl) | 2003-06-12 | 2004-06-10 | Białka fuzyjne |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070253966A1 (pl) |
| EP (1) | EP1641483B1 (pl) |
| JP (1) | JP2007505643A (pl) |
| CN (1) | CN1802167A (pl) |
| AT (1) | ATE385806T1 (pl) |
| AU (1) | AU2004247042A1 (pl) |
| BR (1) | BRPI0411112A (pl) |
| CA (1) | CA2526169A1 (pl) |
| CY (1) | CY1107248T1 (pl) |
| DE (1) | DE602004011770T2 (pl) |
| DK (1) | DK1641483T3 (pl) |
| ES (1) | ES2298785T3 (pl) |
| MX (1) | MXPA05013564A (pl) |
| PL (1) | PL1641483T3 (pl) |
| PT (1) | PT1641483E (pl) |
| SI (1) | SI1641483T1 (pl) |
| WO (1) | WO2004110472A2 (pl) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| CN101665538A (zh) * | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| EA012442B1 (ru) * | 2005-05-13 | 2009-10-30 | Эли Лилли Энд Компани | Пегилированные соединения glp-1 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| AU2007240313B2 (en) | 2006-04-20 | 2012-02-02 | Amgen Inc. | GLP-1 compounds |
| ES2352561T3 (es) * | 2006-06-30 | 2011-02-21 | Conaris Research Institute Ag | Dímeros de sgp 130fc mejorados. |
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| WO2008088422A2 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| ES2742268T3 (es) | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2358749B1 (en) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| EP2443145A1 (en) | 2009-06-17 | 2012-04-25 | Amgen, Inc | Chimeric fgf19 polypeptides and uses thereof |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| JP2013512672A (ja) | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質 |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| EP2460527A1 (en) | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
| RU2013118441A (ru) * | 2010-11-05 | 2014-12-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антидиабетические соединения |
| SG10201601789TA (en) | 2011-03-16 | 2016-04-28 | Amgen Inc | Potent And Selective Inhibitors Of Nav1.3 And Nav1.7 |
| JP4857396B1 (ja) * | 2011-04-13 | 2012-01-18 | 日本製薬株式会社 | 融合蛋白質 |
| UA124083C2 (uk) | 2011-06-28 | 2021-07-21 | ІНГІБРЕКС, Інк. | Злитий серпіновий поліпептид і спосіб його застосування |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| AU2015274574B2 (en) | 2014-06-10 | 2019-10-10 | Amgen Inc. | Apelin polypeptides |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| CN106397569B (zh) * | 2015-08-01 | 2020-09-01 | 深圳红石科创生物科技发展有限公司 | 一种治疗代谢疾病的突变细胞因子融合蛋白 |
| CN108137653B (zh) * | 2015-08-05 | 2021-07-13 | 陕西麦科奥特科技有限公司 | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| ES3014984T3 (en) * | 2017-03-14 | 2025-04-28 | Sunshine Lake Pharma Co Ltd | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| CN109206523A (zh) * | 2018-08-27 | 2019-01-15 | 沣潮医药科技（上海）有限公司 | Tigit免疫粘附素、制备方法及用途 |
| CN109748972B (zh) * | 2019-01-31 | 2021-12-03 | 泉州师范学院 | 一种细胞珠蛋白-人源乳铁蛋白肽融合蛋白、基因及应用 |
| US20220016211A1 (en) | 2020-01-08 | 2022-01-20 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| JP2025535871A (ja) | 2022-09-26 | 2025-10-30 | ウォーターストーン ファーマシューティカルズ（ウーハン）カンパニー，リミティド | Ｆｃ－長鎖脂肪酸鎖を含む超長作用型プラットフォーム |
| WO2024132147A1 (en) | 2022-12-22 | 2024-06-27 | Lifearc | Galanin-2 receptor agonists |
| EP4642793A1 (en) * | 2022-12-29 | 2025-11-05 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| AU3382595A (en) * | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| DK1355942T3 (da) * | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
-
2004
- 2004-06-10 ES ES04753440T patent/ES2298785T3/es not_active Expired - Lifetime
- 2004-06-10 AT AT04753440T patent/ATE385806T1/de not_active IP Right Cessation
- 2004-06-10 BR BRPI0411112-5A patent/BRPI0411112A/pt not_active IP Right Cessation
- 2004-06-10 CA CA002526169A patent/CA2526169A1/en not_active Abandoned
- 2004-06-10 US US10/558,862 patent/US20070253966A1/en not_active Abandoned
- 2004-06-10 AU AU2004247042A patent/AU2004247042A1/en not_active Abandoned
- 2004-06-10 PT PT04753440T patent/PT1641483E/pt unknown
- 2004-06-10 WO PCT/US2004/016611 patent/WO2004110472A2/en not_active Ceased
- 2004-06-10 JP JP2006533432A patent/JP2007505643A/ja active Pending
- 2004-06-10 MX MXPA05013564A patent/MXPA05013564A/es active IP Right Grant
- 2004-06-10 SI SI200430704T patent/SI1641483T1/sl unknown
- 2004-06-10 PL PL04753440T patent/PL1641483T3/pl unknown
- 2004-06-10 DK DK04753440T patent/DK1641483T3/da active
- 2004-06-10 CN CNA2004800159578A patent/CN1802167A/zh active Pending
- 2004-06-10 EP EP04753440A patent/EP1641483B1/en not_active Expired - Lifetime
- 2004-06-10 DE DE602004011770T patent/DE602004011770T2/de not_active Expired - Lifetime
-
2008
- 2008-03-18 CY CY20081100303T patent/CY1107248T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05013564A (es) | 2006-03-09 |
| ATE385806T1 (de) | 2008-03-15 |
| BRPI0411112A (pt) | 2006-07-18 |
| DK1641483T3 (da) | 2008-06-02 |
| CA2526169A1 (en) | 2004-12-23 |
| PT1641483E (pt) | 2008-04-29 |
| US20070253966A1 (en) | 2007-11-01 |
| CY1107248T1 (el) | 2012-11-21 |
| WO2004110472A2 (en) | 2004-12-23 |
| SI1641483T1 (sl) | 2008-08-31 |
| DE602004011770T2 (de) | 2009-02-05 |
| AU2004247042A1 (en) | 2004-12-23 |
| JP2007505643A (ja) | 2007-03-15 |
| CN1802167A (zh) | 2006-07-12 |
| EP1641483B1 (en) | 2008-02-13 |
| DE602004011770D1 (de) | 2008-03-27 |
| EP1641483A2 (en) | 2006-04-05 |
| WO2004110472A3 (en) | 2005-02-03 |
| ES2298785T3 (es) | 2008-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1641483T3 (pl) | Białka fuzyjne | |
| HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
| EP1194164B8 (en) | Prion protein peptides and uses thereof | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| PL377553A1 (pl) | Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów | |
| WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| DE60021254D1 (en) | N-cyanomethylamide als protease inhibitoren | |
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| MY153718A (en) | Formulation of human antibodies for treating tnf-(?) associated disorders | |
| WO2001030381A3 (de) | Verwendung von csf-1-inhibitoren | |
| WO2004074486A3 (en) | Fusion proteins of interferon alpha muteins with improved properties | |
| UA91820C2 (ru) | Терапевтическое применение вариантов хемокинов | |
| AU2003281619A1 (en) | aPC NON-NEUTRALIZING ANTIBODY | |
| PL1636261T3 (pl) | Białka trombopoetynowe o ulepszonych właściwościach | |
| WO2004113386A3 (en) | Modified hirudin proteins and t-cell epitopes in hirudin | |
| ZA200209714B (en) | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV. | |
| AU2002364757A1 (en) | Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases | |
| FR2813606B1 (fr) | Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques | |
| LT2002131A (en) | New use of fir oil for cosmetic | |
| WO2006110367A3 (en) | Methods and compositions for mycoplasma toxins | |
| AU3553700A (en) | Preparation for the treatment of pigmentation disorders | |
| WO2001075021A3 (fr) | Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide |